Cutia Therapeutics (HKG:2487) said its chief executive officer, Zhang Lele, purchased 5,000 shares of the company through the open market for HK$49,280, according to a Monday filing with the Hong Kong bourse.
Zhang also bought 28,000 shares of the company in October for HK$343,932 and has not ruled out the possibility of further purchases.
These aggregate purchases of shares stood at 33,000 shares for a total of HK$393,212, with an average price of about HK$11.916 per share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。